Long-term favorable visual outcomes in patients with large submacular hemorrhage

Prashanth G. Iyer, H. Logan Brooks, Harry W. Flynn

Research output: Contribution to journalArticlepeer-review


Submacular hemorrhage (SMH) has been reported to be toxic to the retina based on animal studies. However, observational studies of patients with neovascular-related SMH and those treated with intravitreal anti-vascular growth factor (anti-VEGF) therapy have shown many favorable visual acuity outcomes. We report two cases of neovascular-related SMH with ten or more years of follow-up. The first case was an 83-year old female with a history of nonexudative age-related macular degeneration in both eyes presenting with sudden decrease in vision (20/400) in her right eye due to a large SMH, treated with anti-VEGF therapy. Over the next following months, there was resolution of the hemorrhage and return of good visual acuity. At 10-year follow-up, visual acuity was 20/30 in the right eye. The second case was a 49-year old female with a history of presumed ocular histoplas- mosis syndrome (POHS), presenting with sudden vision loss (20/400) in her right eye due to large, thick SMH. With observation and intermittent anti-VEGF therapy, there was resolution of the hemorrhage. At 30-year follow-up, visual acuity was 20/20 in the right eye.

Original languageEnglish (US)
Pages (from-to)1189-1192
Number of pages4
JournalClinical Ophthalmology
StatePublished - 2021
Externally publishedYes


  • Age-related macular degeneration
  • Anti-vegf
  • Choroidal neovascularization
  • Presumed ocular histoplasmosis syndrome
  • Retinal toxicity
  • Submacular hemorrhage

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Long-term favorable visual outcomes in patients with large submacular hemorrhage'. Together they form a unique fingerprint.

Cite this